{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/hypercholesterolaemia-familial/","result":{"data":{"firstChapter":{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field c9f9897a-fa24-4644-8ebd-532ac64370a0 --><h1>Hypercholesterolaemia - familial: Summary</h1><!-- end field c9f9897a-fa24-4644-8ebd-532ac64370a0 -->","htmlStringContent":"<!-- begin item 59e721ed-4e99-4b3e-8451-a8da54e58c2d --><!-- begin field 608d5f19-79bd-41aa-842e-5f4b7adee289 --><ul><li>Familial hypercholesterolaemia (FH) is an inherited condition characterized by high cholesterol concentration in the blood. It is present from birth and may lead to early development of atherosclerosis and coronary heart disease (CHD).</li><li>Most people with FH have inherited a defective gene for the condition from one parent only (heterozygous FH). Rarely, an affected person will inherit a genetic defect from both parents (homozygous FH).</li><li>FH should be suspected in an adult if:<ul><li>Total cholesterol concentration is greater than 7.5 mmol/L <em>and/or</em></li><li>There is a personal or family history of premature CHD (an event before 60 years in an index person or first-degree relative [parents, siblings, children]).</li></ul></li><li>Primary care clinicians should systematically search primary care records for people who are at highest risk of FH, including:<ul><li>People younger than 30 years of age with a total cholesterol concentration greater than 7.5 mmol/L <em>and</em></li><li>People aged 30 years or older with a total cholesterol concentration greater than 9.0 mmol/L.</li></ul></li><li>If FH is suspected:<ul><li>Two measurements of low-density lipoprotein (LDL) cholesterol concentration should be taken.</li><li>The person should be assessed for clinical signs of FH, such as<em> </em>tendon xanthomata.</li><li>Secondary hypercholesterolaemia should be excluded.</li><li>The Simon Broome or the Dutch Lipid Clinic Network criteria should be used to make a clinical diagnosis of FH in primary care.</li></ul></li><li>All<em> </em>people with a clinical diagnosis of FH should be referred to a specialist for confirmation of the diagnosis and initiation of cascade testing (which involves identification of affected relatives by DNA testing).</li><li>CHD risk assessment tools should not be used to guide management of people with FH, because they are already at a high risk of premature CHD.</li><li>Adults with confirmed heterozygous FH who are at particularly high risk of a coronary event should also be managed by a specialist. Particularly high risk is defined as the presence of any of the following:<ul><li>Established CHD.</li><li>Family history of premature CHD.</li><li>Two or more other cardiovascular disease risk factors (such as male gender, smoking, hypertension, or diabetes).</li></ul></li><li>Primary care management of other adults with confirmed heterozygous FH involves:<ul><li>Offering lifestyle advice.</li><li>Prescribing lipid-modification therapy (high-intensity statin or ezetimibe) to achieve a target reduction in LDL cholesterol concentration of greater than 50% from baseline.</li><li>Considering the need for antihypertensive treatment in people with hypertension, and the need for aspirin for the primary prevention of CVD.</li><li>Following up the person to assess the efficacy and tolerability of treatment.</li><li>Referring to a specialist where appropriate.</li></ul></li><li>All adults with confirmed homozygous FH should be managed by a specialist.</li><li>All children and young people (up to 15 years of age) with FH should be managed by a specialist, preferably one with expertise in managing FH in children and young people.</li></ul><!-- end field 608d5f19-79bd-41aa-842e-5f4b7adee289 --><!-- end item 59e721ed-4e99-4b3e-8451-a8da54e58c2d -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","aliases":[],"chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","slug":"management","fullItemName":"Management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","aliases":[],"topicSummary":"Familial hypercholesterolaemia (FH) is characterized by a high cholesterol concentration in the blood.","lastRevised":"Last revised in September 2020","nextPlannedReviewBy":"2024-02-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-02","nextPlannedReviewByDisplay":"February 2024","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"}],"chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","slug":"management","fullItemName":"Management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c"}},"staticQueryHashes":["3666801979"]}